Summary of Study ST001686
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001084. The data can be accessed directly via it's Project DOI: 10.21228/M8KH57 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST001686 |
| Study Title | Exposure to per- and polyfluoroalkyl substances associates with altered lipid profile of breast milk (Part 3) |
| Study Summary | In this mother-infant study (n=44) we investigated the levels of PFAS in maternal serum and detailed lipidomic profile in breast milk at birth and at three months using ultra high performance liquid chromatography combined with quadrupole-time-of-flight mass spectrometry. |
| Institute | University of Turku |
| Last Name | Lamichhane |
| First Name | Santosh |
| Address | Tykistökatu 6, FI-20520 Turku, Finland |
| santosh.lamichhane@utu.fi | |
| Phone | 0452299070 |
| Submit Date | 2021-02-08 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzdata.xml |
| Analysis Type Detail | LC-MS |
| Release Date | 2021-10-02 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR001084 |
| Project DOI: | doi: 10.21228/M8KH57 |
| Project Title: | Exposure to per- and polyfluoroalkyl substances and lipid profile of breast milk |
| Project Type: | MS analysis |
| Project Summary: | The objective of this study was to investigate whether the maternal levels of PFAS are associated with lipid composition of human breast milk and further, if the changes in composition have impact on the growth of the infants. |
| Institute: | University of Turku |
| Department: | Turku Bioscience |
| Laboratory: | Turku Metabolomics Center |
| Last Name: | Lamichhane |
| First Name: | Santosh |
| Address: | Tykistökatu 6 , Turku |
| Email: | santosh.lamichhane@utu.fi |
| Phone: | 0452299070 |
| Funding Source: | This study was supported by the Swedish Research Council (grant no. 2016-05176 to T.H and M.O), Formas (grant no. 2019-00869 to T.H and M.O), and the NovoNordiskFoundation (xxx). The EDIA study was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (No. 1DP3DK094338-01 to M.K.), the Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology Research 2012-17, No. 250114 to M.K. and M.O.). Further support was received by the Academy of Finland postdoctoral grant (No. 323171 to S.L.) and the Medical Research Funds, Tampere and Helsinki University Hospitals (to M.K.). |
| Project Comments: | Parts 1, 2 and 3 |
| Contributors: | Santosh Lamichhane, Heli Siljander, Daniel Duberg, Jorma Ilonen, Suvi M. Virtanen, Matej Oreši?, Mikael Knip, Tuulia Hyötyläinen |
Subject:
| Subject ID: | SU001763 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Gender: | Not applicable |
Factors:
Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)
| mb_sample_id | local_sample_id | Sample Code |
|---|---|---|
| SA155453 | 744 _2 | 3 months |
| SA155454 | 757 _2 | 3 months |
| SA155455 | 764 _2 | 3 months |
| SA155456 | 740 _2 | 3 months |
| SA155457 | 673 _2 | 3 months |
| SA155458 | 514 _2 | 3 months |
| SA155459 | 568 _2 | 3 months |
| SA155460 | 776 _2 | 3 months |
| SA155461 | 739 _2 | 3 months |
| SA155462 | 792 _2 | 3 months |
| SA155463 | 1294 _2 | 3 months |
| SA155464 | 1300 _2 | 3 months |
| SA155465 | 1348 _2 | 3 months |
| SA155466 | 969 _2 | 3 months |
| SA155467 | 820 _2 | 3 months |
| SA155468 | 806 _2 | 3 months |
| SA155469 | 808 _2 | 3 months |
| SA155470 | 510 _2 | 3 months |
| SA155471 | 487 _2 | 3 months |
| SA155472 | 226 _2 | 3 months |
| SA155473 | 259 _2 | 3 months |
| SA155474 | 297 _2 | 3 months |
| SA155475 | 201 _2 | 3 months |
| SA155476 | 84 _2 | 3 months |
| SA155477 | 59 _2 | 3 months |
| SA155478 | 72 _2 | 3 months |
| SA155479 | 74 _2 | 3 months |
| SA155480 | 305 _2 | 3 months |
| SA155481 | 327 _2 | 3 months |
| SA155482 | 427 _2 | 3 months |
| SA155483 | 450 _2 | 3 months |
| SA155484 | 471 _2 | 3 months |
| SA155485 | 399 _2 | 3 months |
| SA155486 | 369 _2 | 3 months |
| SA155487 | 333 _2 | 3 months |
| SA155488 | 346 _2 | 3 months |
| SA155489 | 353 _2 | 3 months |
| SA155490 | 18 _2 | 3 months |
| Showing results 1 to 38 of 38 |
Collection:
| Collection ID: | CO001756 |
| Collection Summary: | Blood samples collected for this study were allowed to clot at room temperature. The clot was removed by centrifugation and the resulting supernatant serum samples were stored at −80 °C until analyzed. |
| Sample Type: | Blood (serum) |
Treatment:
| Treatment ID: | TR001776 |
| Treatment Summary: | Sample were stored at -80 as it is, no treatment done. |
Sample Preparation:
| Sampleprep ID: | SP001769 |
| Sampleprep Summary: | 10 µl of serum of was extracted with using a modified version of the previously published Folch procedure. In short, 10 µL of 0.9% NaCl and, 120 µL of CHCl3: MeOH (2:1, v/v) containing the internal standards (c = 2.5 µg/mL) was added to the sample. The standard solution contained the following compounds: 1,2-diheptadecanoyl-sn-glycero-3-phosphoethanolamine (PE(17:0/17:0)), N-heptadecanoyl-D-erythro-sphingosylphosphorylcholine (SM(d18:1/17:0)), N-heptadecanoyl-D-erythro-sphingosine (Cer(d18:1/17:0)), 1,2-diheptadecanoyl-sn-glycero-3-phosphocholine (PC(17:0/17:0)), 1-heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (LPC(17:0)) and 1-palmitoyl-d31-2-oleoyl-sn-glycero-3-phosphocholine (PC(16:0/d31/18:1)), were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA), and, triheptadecanoylglycerol (TG(17:0/17:0/17:0)) was purchased from Larodan AB (Solna, Sweden). The samples were vortex mixed and incubated on ice for 30 min after which they were centrifuged (9400 × g, 3 min). 60 µL from the lower layer of each sample was then transferred to a glass vial with an insert and 60 µL of CHCl3: MeOH (2:1, v/v) was added to each sample. The samples were stored at -80 °C until analysis. |
| Processing Storage Conditions: | -80℃ |
Combined analysis:
| Analysis ID | AN002753 |
|---|---|
| Analysis type | MS |
| Chromatography type | Reversed phase |
| Chromatography system | Waters Acquity UPLC |
| Column | BEH C18 |
| MS Type | ESI |
| MS instrument type | QTOF |
| MS instrument name | Agilent 6210 TOF |
| Ion Mode | NEGATIVE |
| Units | ng/ml |
Chromatography:
| Chromatography ID: | CH002034 |
| Chromatography Summary: | Column name, BEH C18 (2.1 x 100 mm, particle size 1.7 µm) (Waters Corporation, Milford, MA, USA) |
| Instrument Name: | Waters Acquity UPLC |
| Column Name: | BEH C18 |
| Chromatography Type: | Reversed phase |
MS:
| MS ID: | MS002550 |
| Analysis ID: | AN002753 |
| Instrument Name: | Agilent 6210 TOF |
| Instrument Type: | QTOF |
| MS Type: | ESI |
| MS Comments: | Dual jet stream electrospray (dual ESI) ion source was used and the ion polarity was on negative mode. The capillary voltage and the nozzle voltage were kept at 4500 V and 1500 V. The N2 pressure was set on 21 psi, with the sheath gas flow as 11 L/min and temperature at 379°C for the nebulizer. The data was acquired with MassHunter B.06.01 software (Agilent Technologies, Santa Clara, CA, The United States of America). |
| Ion Mode: | NEGATIVE |
